About pyxis oncology inc - PYXS
Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The firm focuses on the development of product candidates to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The company was founded by David Steinberg, Shaan C. Gandhi, and John L. Flavin on June 11, 2018 and is headquartered in Boston, MA.
PYXS At a Glance
Pyxis Oncology, Inc.
321 Harrison Avenue
Boston, Massachusetts 02118
| Phone | 1-617-221-9059 | Revenue | 13.86M | |
| Industry | Pharmaceuticals: Major | Net Income | -79,621,000.00 | |
| Sector | Health Technology | Employees | 56 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
PYXS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 5.157 |
| Price to Book Ratio | 1.35 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.273 |
| Enterprise Value to Sales | 1.574 |
| Total Debt to Enterprise Value | 0.856 |
PYXS Efficiency
| Revenue/Employee | 247,464.286 |
| Income Per Employee | -1,421,803.571 |
| Receivables Turnover | 19.797 |
| Total Asset Turnover | 0.11 |
PYXS Liquidity
| Current Ratio | 3.412 |
| Quick Ratio | 3.412 |
| Cash Ratio | 3.234 |
PYXS Profitability
| Gross Margin | 50.216 |
| Operating Margin | -609.179 |
| Pretax Margin | -564.548 |
| Net Margin | -574.549 |
| Return on Assets | -63.267 |
| Return on Equity | -91.435 |
| Return on Total Capital | -110.46 |
| Return on Invested Capital | -75.869 |
PYXS Capital Structure
| Total Debt to Total Equity | 34.963 |
| Total Debt to Total Capital | 25.906 |
| Total Debt to Total Assets | 19.756 |
| Long-Term Debt to Equity | 31.795 |
| Long-Term Debt to Total Capital | 23.558 |